NCT04135833View on ClinicalTrials.gov

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions

NSCLC

Interventions

DRUG

BPI-7711

BPI-7711 60 mg

DRUG

BPI-7711

BPI-7711 180 mg

DRUG

Itraconazole

Itraconazole 200 mg

DRUG

Rifampicin

Rifampicin 600 mg

Trial Locations (1)

200000

Shanghai Xuhui Central Hospital, Shanghai

Sponsors

Lead Sponsor

Beta Pharma, Inc.

All Listed Sponsors

lead

Beta Pharma, Inc.

INDUSTRY